FUKUOKA UNIVERSITY Patent applications |
Patent application number | Title | Published |
20150191904 | COMPOSITE STRUCTURE - A composite structure includes a plate-like shear resistance member joined to a surface of a substrate in an erected manner and a concrete-based member formed on the surface of the substrate. The plate-like shear resistance member is embedded in the concrete-based member, and a through hole and a projecting rim portion projecting outside of at least one surface of the plate-like shear resistance member from an inner periphery of the through hole are provided on the plate-like shear resistance member. | 07-09-2015 |
20140287000 | TUMOR PROLIFERATION INHIBITOR CONTAINING ULTRASOUND-SENSITIVE SUBSTANCE AND METHOD FOR INHIBITING TUMOR PROLIFERATION BY USING TUMOR PROLIFERATION INHIBITOR AND LOW-INTENSITY PULSED ULTRASOUND WAVES - Provided are a tumor proliferation inhibitor and a method for inhibiting tumor proliferation both of which can be applied to a minimally invasive cancer treatment using low-intensity pulsed ultrasound. The present invention provides a tumor proliferation inhibitor containing an ultrasound-sensitive substance and an acoustic cavitation phenomenon-enhancing substance, and provides a method for inhibiting tumor proliferation that can exhibit a tumor proliferation-inhibitory effect using the tumor proliferation inhibitor in combination with low-intensity pulsed ultrasound of a degree that is used in ultrasound diagnosis, and that can be applied to a minimally invasive cancer treatment using low-intensity pulsed ultrasound. | 09-25-2014 |
20140256820 | THERAPEUTIC AGENT FOR BLOOD-BRAIN BARRIER DISRUPTION SYNDROME - A medicinal agent or a pharmaceutical composition, each of which comprises a biguanides agent or a pharmaceutically acceptable salt thereof as an active ingredient, and which can potentiate blood-brain barrier functions including tight junction capability and transcellular transport capability of a brain capillary endothelial cell and therefore can treat blood-brain barrier dysfunction syndrome. | 09-11-2014 |
20140045053 | DISPERSANT, DISPERSION, METHOD FOR ADJUSTING VISCOSITY OF DISPERSANT, MOBILE DEVICE, SURFACE TREATMENT AGENT, ELECTROLYTIC SOLUTION, SEPARATOR, AND RECHARGEABLE LITHIUM ION BATTERY - A dispersant of the present invention is used after being added to a dispersant obtained by dispersing fine particles of a crystalline polymer as a dispersed particle and is characterized by containing a copolymer of a first monomer and a second monomer, the first monomer being a monomer that can be crystallized as a polymer having the molecular structure identical to that of the dispersed particle. | 02-13-2014 |
20130316429 | ANTI-APOPTOSIS OR ANTI-NECROSIS INDUCTION METHOD - Disclosed herein is a method for simply inducing an anti-apoptotic effect and/or an anti-necrotic effect in a living cell with good control without administering any drug. The method includes applying an alternating-current voltage to the living cell so that an electric current of 25 μA or higher but 75 μA or lower flows to induce an anti-apoptotic effect and/or an anti-necrotic effect in the living cell. The living cell used may be a cultured cell. The alternating-current voltage may be applied to a stage member on which a container holding the living cell is placed. | 11-28-2013 |
20130231576 | SOMATIC DATA-MEASURING APPARATUS AND SOMATIC DATA MEASUREMENT METHOD - Provided are a somatic data-measuring apparatus that can easily and accurately measure the optimal exercise intensity for the subject being measured, and a somatic data measurement method. The somatic data-measuring apparatus is provided with a heart sound-acquiring means that detects the subject's heart sounds and outputs same as heart sound data, a first heart sound-extracting means that detects the first heart sound on the basis of the heart sound data, a first heart sound amplitude-measuring means that measures the amplitude from the detected first heart sound and outputs same as first heart sound amplitude data, a heart rate-counting means that measures the subject's heart rate and outputs same as heart rate data, and an exercise intensity-computing means that computes the double product of the heart rate data and the first heart sound amplitude data as double product data and detects, as the optimal exercise intensity, the exercise intensity at which the approximation line, which approximates said double product data distribution, bends. Since the double product, which represents myocardial oxygen consumption, is effective as an index that accurately reflects the state of cardiac workload, it is possible to measure accurately the degree of workload on the heart. | 09-05-2013 |
20130211195 | ENDOSCOPIC OBSERVATION METHOD AND COMPOSITION FOR IMPROVING DIAGNOSTIC PERFORMANCE INVOLVING APPLYING USEFUL WHITE OPAQUE SUBSTANCE TO DIAGNOSIS OF GASTRIC EPITHELIAL TUMORS (ADENOMA OR GASTRIC CANCER) - To develop a clinically useful composition and an endoscopic observation method that utilizes WOS properties. The composition for improving diagnostic performance, containing lipids as a component is characterized in that, by administering or loading said composition orally, by intubation or via an endoscope, the lipids are absorbed by gastric tumors, facilitating the detection of tumors and qualitative diagnoses by endoscope. Tumors are thus whitened by administering or loading this composition for improving diagnostic performance prior to endoscopic observation, making it easier to discover and qualitatively diagnose tumors by endoscopic observation. | 08-15-2013 |
20130129799 | TUMOR PROLIFERATION INHIBITOR CONTAINING ULTRASOUND-SENSITIVE SUBSTANCE AND METHOD FOR INHIBITING TUMOR PROLIFERATION BY USING TUMOR PROLIFERATION INHIBITOR AND LOW-INTENSITY PULSED ULTRASOUND WAVES - Provided are a tumor proliferation inhibitor and a method for inhibiting tumor proliferation both of which can be applied to a minimally invasive cancer treatment using low-intensity pulsed ultrasound. The present invention provides a tumor proliferation inhibitor containing an ultrasound-sensitive substance and an acoustic cavitation phenomenon-enhancing substance, and provides a method for inhibiting tumor proliferation that can exhibit a tumor proliferation-inhibitory effect using the tumor proliferation inhibitor in combination with low-intensity pulsed ultrasound of a degree that is used in ultrasound diagnosis, and that can be applied to a minimally invasive cancer treatment using low-intensity pulsed ultrasound. | 05-23-2013 |
20130094490 | WIRELESS COMMUNICATION APPARATUS - A wireless communication apparatus has a first communication unit configured to perform at least one of transmission and reception by using a multicarrier signal constituted by a plurality of subcarriers shaped by a band-limited pulse waveform; and second communication unit configured to perform at least one of transmission and reception by using a signal having a different modulation format or modulation constant from said signal of said first communication unit. Said first communication unit configured to perform communication without using at least one of said plurality of subcarriers, and said second communication unit configured to perform communication using a band of said subcarrier not used by said first communication unit. | 04-18-2013 |
20120270177 | DENTAL ULTRASONIC DRUG DELIVERY SYSTEM AND DENTAL ULTRASONIC DRUG DELIVERY METHOD - A dental ultrasonic drug delivery system capable of accurately cleaning the inside of root canals and killing bacteria in dentin tubules is provided. The dental ultrasonic drug delivery system delivers a drug to a target using an ultrasonic delivery device | 10-25-2012 |
20110237807 | ROTAXANE COMPOUND AND ANTITUMOR AGENT - An antitumor agent which is not easily excreted from tumor cells and is suitable for a topical treatment. Specifically disclosed is a rotaxane compound with contains a compound represented by chemical formula 1 as the base structure. (In chemical formula 1, m≧2, n≧3, and X represents an anionic molecule or an anionic atom | 09-29-2011 |
20110237647 | INHIBITORY RNA FOR MODULATING THE MOLECULAR FUNCTION OF ZFAT GENE - The inhibitory RNA for inhibiting the expression of ZFAT gene according to this invention is a siRNA comprising a sense RNA having a base sequence of contiguous 20 to 20 bases, preferably 23 to 27 bases, of ZFAT mRNA and an anti-sense RNA having a base sequence complementary to the base sequence of the sense RNA or a shRNA comprising a double-stranded RNA (dsRNA) with the sense RNA connected to the anti-sense RNA via a loop sequence. | 09-29-2011 |
20110059024 | LIPOSOME COMPOSITION, AND DIAGNOSTIC CONTRAST AGENT, THERAPEUTIC ENHANCER, AND PHARMACEUTICAL COMPOSITION USING THE SAME - To provide a liposome composition, which contains at least one liposome, gas entrapped in the liposome, and at least one fullerene encapsulated in or adsorbed on the liposome. | 03-10-2011 |
20110059020 | LIPOSOME COMPOSITION, AND DIAGNOSTIC CONTRAST AGENT, THERAPEUTIC ENHANCER, AND PHARMACEUTICAL COMPOSITION USING THE SAME - To provide a liposome composition, which contains at least one liposome; gas entrapped in the liposome, and at least one metal oxide particle encapsulated in or adsorbed on the liposome, wherein the liposome composition satisfies a ratio B/A of 0.01 to 5, where A is a volume of the gas contained in the liposome on the basis of micro liter, and B is a mass of the at least one metal oxide particle contained in the liposome on the basis of milligram. | 03-10-2011 |
20110015440 | PHOSPHINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND PEROXIDE SCAVENGER USING THE SAME - The invention provides a novel peroxide scavenger comprising a phosphine compound represented by general formula [I]: | 01-20-2011 |
20100217006 | Inhibitor Of Ischemic Disorders - It is intended to provide a drug which is efficacious in treating and preventing diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof. Because of containing as the active ingredient a substance selected from among farnesol, a farnesol derivative, a tocopherol derivative, a tocotrienol derivative, pharmacologically acceptable salts thereof and solvates thereof, the above-described inhibitor of ischemic disorders can exert therapeutic and preventive effects on diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof (for example, brain infarction, brain edema, cardiac infarction, etc.) not only by the administration in the acute ischemic stage but also by the therapeutic administration in subacute and/or chronic stages after ischemia-reperfusion. It is also intended to provide a farnesol carboxylic acid ester derivative and a method of producing the same. | 08-26-2010 |
20100173277 | Agent for Suppressing Rejection in Organ Transplantation Comprising Anti-HMGB-1 Antibody - An objective of the present invention is to provide effective methods for suppressing rejection in organ transplantation, in particular, pancreatic islet transplantation which is useful in treating diabetes. The present invention demonstrated that antibodies against HMGB-1 suppressed the rejection in pancreatic islet transplantation and promoted the survival of grafted pancreatic islets. Thus, the present invention provides agents that comprise an anti-HMGB-1 antibody for suppressing rejection in organ transplantation. | 07-08-2010 |
20100048512 | RADIATION PROTECTION DRUG CONTAINING TOCOPHEROL OR TOCOTRIENOL COMPOUND ESTER DERIVATIVE AS ACTIVE INGREDIENT - Administration of either a tocopherol represented by the general formula (1) or a tocotrienol compound ester derivative before or after exposure to radiation is effective in preventing or treating health disorders caused by the radiation exposure. | 02-25-2010 |
20090220499 | Agents for Suppressing Damage to Transplanted Islets After Islet Transplantation - The present inventors investigated anti-IL-6 receptor antibodies for their effect in suppressing damage to transplanted islets after islet transplantation. As a result, they found that anti-IL-6 receptor antibodies reduced damage to transplanted islets, improved islet survival, and corrected hyperglycemia in recipients. Further, they revealed that administration of the anti-IL-6 receptor antibodies of the present invention suppressed the production of inflammatory cytokines by infiltrating cells after transplantation. Specifically, the present inventors discovered for the first time that damage to transplanted islets after islet transplantation can be suppressed by using anti-IL-6 receptor antibodies according to the present invention. | 09-03-2009 |